赛诺哈勃药业

SinoHub Pharmaceutical is a Beijing-based biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases and pediatric conditions, particularly within the central nervous system (CNS) therapeutic area. The company gained prominence by launching the first domestic vigabatrin powder for oral solution in China, providing a vital treatment option for infants suffering from West syndrome (infantile spasms). SinoHub's strategic focus involves addressing significant unmet medical needs through the development of a robust pipeline of small molecule therapies for refractory epilepsy syndromes, including Dravet syndrome and Lennox-Gastaut syndrome. By utilizing China's accelerated regulatory pathways for orphan drugs, the company aims to establish itself as a leader in the domestic rare disease market. SinoHub is supported by prominent venture capital firms and maintains integrated capabilities spanning research, clinical development, and commercial operations.